Last week ended with another Friday night blitz of biotech S-1s as a fresh wave of new offerings forms to crash into Nasdaq. Entering the Wall Street spotlight now is one transatlantic operation that is out to develop a new class of meds, a Dallas biotech with a Phase III kidney cancer drug and a startup that in-licensed its lead drug from Novartis.
{iframe}https://endpts.com/three-biotechs-reveal-some-secrets-about-themselves-as-they-gun-for-271m-plus-in-ipos/{/iframe}